OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

CompletedOBSERVATIONAL
Enrollment

74

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Liver Transplant
Interventions
DEVICE

OCS Liver

Transplant with an OCS preserved liver.

Trial Locations (11)

10029

Mount Sinai, New York

21205

Johns Hopkins, Baltimore

23298

Virginia Commonwealth University Health System, Richmond

68198

University of Nebraska Medical Center, Omaha

75390

University of Texas Southwest, Dallas

77030

Houston Methodist Hospital, Houston

78229

The University of Texas Health Science Center at San Antonio, San Antonio

92037

Scripps, La Jolla

University of California San Diego, La Jolla

94143

University of California San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

TransMedics

INDUSTRY

NCT05096754 - OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study | Biotech Hunter | Biotech Hunter